

JUN 20 2003



K03 18 71

GE Medical Systems

## **510(k) SUMMARY OF SAFETY AND EFFECTIVENESS**

This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR Part 807.87(h).

**Submitter**                Larry A. Kroger, Ph.D.  
Senior Regulatory Programs Manager  
Telephone: (262) 544-3894  
Fax: (262) 548-4768  
GE Medical Systems W-400  
3000 North Grandview Blvd.  
Waukesha, WI 53188 USA  
Date Prepared: March 25, 2003.

## **PRODUCT IDENTIFICATION**

Name:                      AutoBone

Classification Name:    Accessory to Computed Tomography System

Manufacturer :            General Electric Medical Systems  
283, rue de la Minière  
78533 Buc Cedex, FRANCE

Distributor:              General Electric Medical Systems, Buc, France.

**Marketed Devices**    The AutoBone is substantially equivalent to the devices listed below:

Model:	<b>Volume Rendering</b>
Manufacturer:	General Electric Medical Systems, Milwaukee, WI
510(k) #:	<b>K972399</b>
Model:	<b>Vitre 2</b>
Manufacturer:	Vital Images
510(k) #:	<b>K002519</b>

## **Device Description:**

AutoBone is an optional software extension of the Volume Viewer application for Advantage Workstation. This software can be used in order to facilitate visualization of vessel features and assist in segmentation of bony structures

**Indications for Use:**

The **AutoBone** option is a software package that is intended to facilitate segmentation of bony structures from abdominal and extremity CT Angiography data. It runs on Advantage Workstations, revision 4.1 or higher .

**Comparison with Predicate:**

AutoBone is an image analysis software package that is intended to facilitate segmentation of bony structures from abdominal and extremity CT Angiography data. The functional features of this package are substantially equivalent to that of the following devices:

Device Name	FDA Clearance Number
Volume Rendering	K972399
Vitreia 2	K002519

**Adverse Effects on Health:**

The potential hazards are identified in a risk management summary (hazard analysis) and are controlled by:

- Software Development, Validation and Verification Process to ensure performance to specifications, Federal Regulations and user requirements.
- Adherence to industry and international standards.

**Conclusions:**

The AutoBone does not result in any new potential safety risks and performs as well as devices currently on the market. GE considers features of the AutoBone to be equivalent to those of Volume Rendering (K972399) and Vitrea 2 ( K002519).



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUN 20 2003

GE Medical Systems  
% Mr. Wolfram Gmelin  
Third Party Reviewer  
TÜV Rheinland of North America  
12 Commerce Road  
NEWTOWN CT 06470

Re: K031871  
Trade/Device Name: AutoBone  
Regulation Number: 21 CFR 892.1750  
Regulation Name: Computed tomography  
x-ray system  
Regulatory Class: II  
Product Code: 90 JAK  
Dated: May 5, 2003  
Received: June 17, 2003

Dear Mr. Gmelin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

*General Electric Medical Systems***STATEMENT OF INTENDED USE****Device name:** AutoBone**Intended Use:**

The AutoBone option is a software package that is intended to facilitate segmentation of bony structures from abdominal and extremity CT Angiography data. It runs on Advantage Workstations, revision 4.1 or higher

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓  
(Per 21 CFR 801.109)

-OR-

Over-The-Counter Use \_\_\_\_\_

David A. Seymour  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K031871